GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RetinalGenix Technologies Inc (OTCPK:RTGN) » Definitions » Intangible Assets

RetinalGenix Technologies (RetinalGenix Technologies) Intangible Assets : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is RetinalGenix Technologies Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. RetinalGenix Technologies's intangible assets for the quarter that ended in Mar. 2024 was $0.00 Mil.


RetinalGenix Technologies Intangible Assets Historical Data

The historical data trend for RetinalGenix Technologies's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RetinalGenix Technologies Intangible Assets Chart

RetinalGenix Technologies Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Intangible Assets
- - - -

RetinalGenix Technologies Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

RetinalGenix Technologies Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


RetinalGenix Technologies  (OTCPK:RTGN) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


RetinalGenix Technologies Intangible Assets Related Terms

Thank you for viewing the detailed overview of RetinalGenix Technologies's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


RetinalGenix Technologies (RetinalGenix Technologies) Business Description

Traded in Other Exchanges
N/A
Address
1450 North McDowell Boulevard, Suite 150, Petaluma, CA, USA, 94954
RetinalGenix Technologies Inc is an ophthalmic research and development company focused on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders, Its mission is to prevent vision loss and blindness due to diabetic retinopathy and maculopathy through early detection from the use of two devices: (1) Retinal Imaging Screening Device (RetinalGenixTM), being designed as a portable, high-resolution retinal imaging Diabetic screening system providing a 200-degree field of view without requiring pupil dilation; and (2) RetinalCamTM, being designed as a high-resolution home monitoring retinal imaging device and physician alert system offering real-time communication with physicians available 24/7.